Market Research Report
EUROPE ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||492772|
|Published||Content info||72 Pages
Delivery time: 2-3 business days
|EUROPE ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026|
|Published: August 6, 2018||Content info: 72 Pages||
The spectrum of fungal infections ranges from the localized skin and soft tissue infections to fungemia, with disseminated disease to almost any organ system. In recent years, the prevalence of such infections has multiplied considerably, thus increasing the market demand for antifungal agents. Over the estimated period of 2018-2026, the Europe antifungal agents market is forecasted to rise with a CAGR of 3.23%.
Rising popularity of over-the-counter drugs segment has helped in boosting the market growth. Also, rapid growth and rising concerns of peoples regarding health and infectious diseases are fueling the market demand for antifungal agents. Of all the countries analyzed in this report for the Europe anti-fungal agents market, the Austrian market is likely to register the highest CAGR by the end of the projected years. The other significant market in this region is Germany, which accounted for the highest revenue share in 2017.
Leading market players in this region include Baxter, Abbott Laboratories, Novartis, Gilead, Arbor Pharmaceuticals Inc., Teva Pharmaceuticals, GlaxoSmithKline, Pfizer, Bayer Healthcare, Sanofi- Aventis, Merck Co, Johnson & Johnson, Astellas Pharma Inc., Kramer Laboratories, and Vertex Pharmaceuticals.